Introduction
============

PAPA syndrome (Pyogenic Arthritis, Pyoderma gangrenosum, and Acne) is an ultra-rare autosomal dominant, auto-inflammatory disease associated to mutations in the PSTPIP1/CD2BP1 gene. The therapeutic approach during recurrences consists of steroids, while no agreement exists on the chronic management. Evidences on the use of biologics are anecdotal and variable results have been reported.

Objectives
==========

To evaluate the long-term response to treatment with IL1 antagonist in six patients affected by PAPA syndrome.

Methods
=======

Six patients (M:F=3:3; 4 pediatric, 1 young adult and 1 adult, mean age 18 years, range 3-50) affected by PAPA syndrome were enrolled and treated with IL1 blockers (5 patients Anakinra, 1 patient Anakinra followed by Canakinumab). Three patients were already treated with anti-TNFα monoclonal antibodies without benefit. Data were collected retrospectively (mean follow-up 26 months, range 4-38). The frequency of articular and cutaneous flares in the 24 months before starting therapy where compared to those occurred during anti-IL1 regimen. Acute phase reactants (ESR, CRP, SAA) were assessed at the last visit before the study enrolment and at last follow-up.

Results
=======

All the patients displayed a significant decrease in frequency of disease flares (Table [1](#T1){ref-type="table"}) and normalization of acute phase reactants. Three patients were asymptomatic during whole follow-up. Patient \#5, with a severe and persistent pyoderma gangrenosum, displayed a partial response to Anakinra partially due to a poor compliance to daily s.c. administration. The shift to Canakinumab lead to a fast and complete resolution of the skin manifestations.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pt   Sex   Mutation   Main manifestations         Manifestations in the 24 months before treatment   N± of flares during follow-up                         Treatment (dose, duration)
  ---- ----- ---------- --------------------------- -------------------------------------------------- ----------------------------------------------------- ----------------------------------
  1    F     E256G      Pyogenic arthritis\         2 flares of pyogenic arthritis\                    0                                                     Anakinra\
                        Pyoderma gangrenosum\       5 pyoderma gangrenosum\                                                                                  100 mg/day\
                        Cystic acne/foruncolosis    Cystic acne                                                                                              (36 months)

                                                                                                                                                             

  2    F     E250Q      Pyogenic arthritis\         3 flares of pyogenic arthritis\                    0                                                     Anakinra\
                        Sterile osteomyelitis\      1 sterile osteomyelitis\                                                                                 2 mg/kg/day\
                        Palpebral edema             1 palpebral edema                                                                                        (21 months)

                                                                                                                                                             

  3    M     E250Q      Pyogenic arthritis          7 flares of pyogenic arthritis (polyarticular)     3 (mild) articular flares                             Anakinra\
                                                                                                                                                             1.5 mg/kg/day\
                                                                                                                                                             (38 months) and low dose steroid

                                                                                                                                                             

  4    M     WT         Cutaneous abscesses\        1 persistent muscular abscess                      0                                                     Anakinra\
                        Pyoderma gangrenosum\                                                                                                                100 mg/day\
                        Pyogenic muscular abscess                                                                                                            (26 months)

                                                                                                                                                             

  5    M     E250K      Pyogenic arthritis\         1 cutaneous abscess\                               1 pyoderma gangrenosum (resolved after Canakinumab)   Anakinra\
                        Pyoderma gangrenosum\       3 pyoderma gangrenosum\                                                                                  2 mg/kg/day\
                        Severe anemia\              Anemia                                                                                                   (31 months)\
                        Splenomegaly\                                                                                                                        -\
                        Growth delay                                                                                                                         Canakinumab\
                                                                                                                                                             (4 months)

                                                                                                                                                             

  6    F     E250Q      Dactylitis/tendinitis\      6 articular flares                                 0                                                     Anakinra\
                        Pyogenic arthritis\                                                                                                                  100 mg/day\
                        Acne and furunculosis                                                                                                                (4 months)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Conclusions
===========

The long-term use of IL1 blockers is associated to satisfactory and persistent control of clinical manifestations and laboratory findings in PAPA syndrome.
